The University of Southampton
University of Southampton Institutional Repository
Warning ePrints Soton is experiencing an issue with some file downloads not being available. We are working hard to fix this. Please bear with us.

Plant viral vaccine delivery as a platform to induce cellular immunity against cancer antigens

Plant viral vaccine delivery as a platform to induce cellular immunity against cancer antigens
Plant viral vaccine delivery as a platform to induce cellular immunity against cancer antigens
Immunotherapy with immunostimulatory antibodies has become a breakthrough therapeutic modality for solid tumours. However, only up to 50% of patients benefit and hence there is a renewed interest to vaccination to direct the immune attack against tumour antigens to widen the range of patients who benefit. Modern vaccine platforms such as viral-like particles have already demonstrated success in cancer prevention and the challenge is now to harness these approaches in patients with established malignancies. We have focused on a novel vaccine platform utilising a plant viral particle (PVP), which has been previously demonstrated that this single strand RNA (ssRNA) containing vaccine activated the immune mechanisms closely resembling the natural antiviral defence. Based on our previous mouse work, with sensing of viral RNA by plasmacytoid dendritic cells (pDCs), IFN-α was generated to activate conventional DCs (cDCs), and then prime Th1 immunity. We also confirmed that PVP with ssRNA packaged inside was capable to activate human DCs. The induction of anti-tumour antibody was another outcome. Subsequently, we explored this vaccine platform for induction of cellular responses against defined cancer targets. Initially using PVP loaded with a single model peptide, the induction of a rapid CD8 response of high magnitude was represented. In order to extend the application of this platform, the clinically relevant cancer testis antigens MAGEC1 and PASD1 were set as vaccine targets. In HLA-A2 transgenic (HHD) mouse model, PVP simultaneously targeting MAGEC1 and PASD1 induced CTLs, which were able to lyse human cancer cells expressing these antigens. We were accordingly keen to expend applicability to patient cohorts beyond HLA-A2+ patients, PVP loaded with whole protein antigens was subsequently tested. The vaccine induced CD8 and CD4 T-cell responses against epitopes delivered through the whole antigen were both detected. Of these, this flexible and economical platform can be adapted easily to deliver any antigenic peptides including multiple epitopes as well as whole proteins and may provide a universal platform for vaccination against cancer.
Wang, Chuan
f293763a-7eba-4d8e-a496-3b5e25a1a171
Wang, Yidao
34466a09-d91e-48e2-91db-3a39f6dffa8d
Allen, Alexandra J
660f61b5-0ccc-46f6-a638-4495d7ae7686
Jobsri, Jantipa
7b728390-2124-4a91-a7a5-77e4426b947b
Ottensmeier, Christian. H
42b8a398-baac-4843-a3d6-056225675797
Sahota, Surinder
66c1457f-cba2-4c49-9c8c-fcee0748b6b8
Savelyeva, Natalia
804c3e15-d260-4717-9b7c-15c16ba87fc7
Wang, Chuan
f293763a-7eba-4d8e-a496-3b5e25a1a171
Wang, Yidao
34466a09-d91e-48e2-91db-3a39f6dffa8d
Allen, Alexandra J
660f61b5-0ccc-46f6-a638-4495d7ae7686
Jobsri, Jantipa
7b728390-2124-4a91-a7a5-77e4426b947b
Ottensmeier, Christian. H
42b8a398-baac-4843-a3d6-056225675797
Sahota, Surinder
66c1457f-cba2-4c49-9c8c-fcee0748b6b8
Savelyeva, Natalia
804c3e15-d260-4717-9b7c-15c16ba87fc7

Wang, Chuan, Wang, Yidao, Allen, Alexandra J, Jobsri, Jantipa, Ottensmeier, Christian. H, Sahota, Surinder and Savelyeva, Natalia (2017) Plant viral vaccine delivery as a platform to induce cellular immunity against cancer antigens. Virus-Like Particle & Nano-Particle Vaccines 2017, Biopolis, Singapore, Singapore. 29 Nov - 01 Dec 2017.

Record type: Conference or Workshop Item (Other)

Abstract

Immunotherapy with immunostimulatory antibodies has become a breakthrough therapeutic modality for solid tumours. However, only up to 50% of patients benefit and hence there is a renewed interest to vaccination to direct the immune attack against tumour antigens to widen the range of patients who benefit. Modern vaccine platforms such as viral-like particles have already demonstrated success in cancer prevention and the challenge is now to harness these approaches in patients with established malignancies. We have focused on a novel vaccine platform utilising a plant viral particle (PVP), which has been previously demonstrated that this single strand RNA (ssRNA) containing vaccine activated the immune mechanisms closely resembling the natural antiviral defence. Based on our previous mouse work, with sensing of viral RNA by plasmacytoid dendritic cells (pDCs), IFN-α was generated to activate conventional DCs (cDCs), and then prime Th1 immunity. We also confirmed that PVP with ssRNA packaged inside was capable to activate human DCs. The induction of anti-tumour antibody was another outcome. Subsequently, we explored this vaccine platform for induction of cellular responses against defined cancer targets. Initially using PVP loaded with a single model peptide, the induction of a rapid CD8 response of high magnitude was represented. In order to extend the application of this platform, the clinically relevant cancer testis antigens MAGEC1 and PASD1 were set as vaccine targets. In HLA-A2 transgenic (HHD) mouse model, PVP simultaneously targeting MAGEC1 and PASD1 induced CTLs, which were able to lyse human cancer cells expressing these antigens. We were accordingly keen to expend applicability to patient cohorts beyond HLA-A2+ patients, PVP loaded with whole protein antigens was subsequently tested. The vaccine induced CD8 and CD4 T-cell responses against epitopes delivered through the whole antigen were both detected. Of these, this flexible and economical platform can be adapted easily to deliver any antigenic peptides including multiple epitopes as well as whole proteins and may provide a universal platform for vaccination against cancer.

Text
Abstract Chuan Wang - Version of Record
Restricted to Registered users only
Download (15kB)
Request a copy

More information

Accepted/In Press date: 30 June 2017
Published date: December 2017
Venue - Dates: Virus-Like Particle & Nano-Particle Vaccines 2017, Biopolis, Singapore, Singapore, 2017-11-29 - 2017-12-01

Identifiers

Local EPrints ID: 417130
URI: http://eprints.soton.ac.uk/id/eprint/417130
PURE UUID: dd0b5462-0141-4a11-8659-824ab9788bb7

Catalogue record

Date deposited: 19 Jan 2018 17:30
Last modified: 21 Nov 2021 10:14

Export record

Contributors

Author: Chuan Wang
Author: Yidao Wang
Author: Alexandra J Allen
Author: Jantipa Jobsri
Author: Surinder Sahota

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×